Technical analysis of Genelux Corporation (GNLX): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer.
Price Performance
| 1 month | -10.00% |
| 3 months | -21.21% |
| Year-to-date | -46.33% |
| 1 year | -40.15% |
| 3 years | -90.78% |
52-Week Range
| 52-week High | $8.54 |
| 52-week Low | $2.29 |
| Avg Volume (90d) | 244K |
Technical Indicators
| SMA 50 | $2.74 |
| SMA 200 | $2.97 |
| Beta | 0.46 |
| 30-day Volatility (annualised) | 59.4% |
| Price vs SMA 50 | -14.7% |
| Price vs SMA 200 | -21.1% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $8.08 | |
| 2025-11 | $5.56 | -31.2% |
| 2025-12 | $4.36 | -21.6% |
| 2026-01 | $2.66 | -39.0% |
| 2026-02 | $2.98 | +12.0% |
| 2026-03 | $2.42 | -18.8% |
| 2026-04 | $2.67 | +10.3% |
| 2026-05 | $3.05 | +14.2% |
| 2026-06 | $3.01 | -1.3% |
| 2026-07 | $2.94 | -2.3% |
| 2026-08 | $2.62 | -10.9% |
| 2026-09 | $2.34 | -10.7% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | | |
| 2026-09-14 | | $563M |
| 2026-09-14 | | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $0.20 | $23M |
| 2026-09-14 | | |
Price
| Price | $2.34 |
| Market Cap | $105M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 5.99 |
| EV / EBITDA | -3.00 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.15 |
| Current Ratio | 2.39 |